Synthesis and Evaluation of 64Cu-Labeled Monomeric and Dimeric NGR Peptides for MicroPET Imaging of CD13 Receptor Expression

详细信息    查看全文

• 作者：Kai Chen ; Wenhui Ma ; Guoquan Li ; Jing Wang ; Weidong Yang ; Li-Peng Yap ; Lindsey D. Hughes ; Ryan Park ; Peter S. Conti
• 刊名：Molecular Pharmaceutics
• 出版年：2013
• 出版时间：January 7, 2013
• 年：2013
• 卷：10
• 期：1
• 页码：417-427
• 全文大小：489K
• 年卷期：v.10,no.1(January 7, 2013)
• ISSN：1543-8392

文摘

The NGR-containing peptides have been shown to bind specifically to CD13/aminopeptidase N (APN) receptor, one of the attractive tumor vasculature biomarkers. In this study, we evaluated ⁶⁴Cu-labeled monomeric and dimeric NGR peptides for microPET imaging of CD13 receptor expression in vivo. Western blot analysis and immunofluorescence staining were performed to identify CD13-positive and CD13-negative cell lines. NGR-containing peptides were conjugated with 1,4,7,10-tetraazadodecane-N,N鈥?N鈥?N鈥?tetraacetic acid (DOTA) and labeled with ⁶⁴Cu (t_1/2 = 12.7 h) in ammonium acetate buffer. The resulting monomeric (⁶⁴Cu-DOTA鈥揘GR1) and dimeric (⁶⁴Cu-DOTA鈥揘GR2) peptides were then subjected to in vitro stability, cell uptake and efflux, small animal micorPET, and biodistribution studies. In vitro studies demonstrated that CD13 receptors are overexpressed in human fibrosarcoma HT-1080 cells and negative in human colon adenocarcinoma HT-29 cells. The binding affinity of ⁶⁴Cu-DOTA鈥揘GR2 to HT-1080 cells was measured to be within low nanomolar range and about 2-fold higher than that of ⁶⁴Cu-DOTA鈥揘GR1. For small animal microPET studies, ⁶⁴Cu-DOTA鈥揘GR2 displayed more favorable in vivo performance in terms of higher tumor uptake and slower tumor washout in CD13-positive HT-1080 tumor xenografts as compared to ⁶⁴Cu-DOTA鈥揘GR1. As expected, significantly lower tumor uptake and poorer tumor/normal organ contrast were observed for both ⁶⁴Cu-DOTA鈥揘GR1 and ⁶⁴Cu-DOTA鈥揘GR2 in CD13-negative HT-29 tumor xenografts in comparison with those in the HT-1080 tumor xenografts. The CD13-specific tumor activity accumulation of both ⁶⁴Cu-DOTA鈥揘GR1 and ⁶⁴Cu-DOTA鈥揘GR2 was further demonstrated by significant reduction of tumor uptake in HT-1080 tumor xenografts with a coinjected blocking dose of cyclic NGR peptide [c(CNGRC)]. The biodistribution results were consistent with the quantitative analysis of microPET imaging. We concluded that both ⁶⁴Cu-DOTA鈥揘GR1 and ⁶⁴Cu-DOTA鈥揘GR2 have good and specific tumor uptake in CD13-positive HT-1080 tumor xenografts. ⁶⁴Cu-DOTA鈥揘GR2 showed higher tumor uptake and better tumor retention than ⁶⁴Cu-DOTA鈥揘GR1, presumably due to bivalency effect and increase in apparent molecular size. ⁶⁴Cu-DOTA鈥揘GR2 is a promising PET probe for noninvasive detection of CD13 receptor expression in vivo.

Keywords:

microPET imaging; NGR peptide; CD13; tumor angiogenesis; bivalency effect; ⁶⁴Cu labeling